ReviewAnnals of the New York Academy of Sciences2015
Mechanisms of echinocandin antifungal drug resistance.
Review in Annals of the New York Academy of Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 302 citations in OpenAlex.
- Rethinking the immune recognition of cell walls in human fungal pathogens: Mechanisms, controversies and translational significance.Virulence · 2026Review
- Slt2 kinase of the cell wall integrity pathway is required for Fks2-specific echinocandin resistance inMicrobiology spectrum · 2026Article
- A multi-barrier defence strategy using plant-derived antifungals against mycotoxigenic fungi in livestock feed.Archives of microbiology · 2026Review
- Emerging evidence for a multitude of mechanisms and factors that determine amphotericin B resistance in pathogenic fungi.Cell surface (Amsterdam, Netherlands) · 2026Review
- Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin inJAC-antimicrobial resistance · 2026Article
- Docking prediction, molecular dynamics and antibiofilm effect of linalool against Candida albicans strains from vulvovaginal secretionsBiomedica : revista del Instituto Nacional de Salud · 2026Article
- α-1,3-Glucan-Driven Remodeling of the Conidial Cell Wall in anJournal of the American Chemical Society · 2026Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- Ribosome-associated proteins in fungal ribosome homeostasis: Conceptual opportunities for peptide-based modulation.Journal of microbiology (Seoul, Korea) · 2026Review
- Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.Microbiology (Reading, England) · 2026Article
- Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals.Journal of fungi (Basel, Switzerland) · 2026Review
- Inhibition mechanism of the fungal β-1,3-glucan synthases by triterpenoid antifungal drugs.Nature communications · 2026Article
- Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans.PloS one · 2026Article
- The fungal stronghold: biofilms in hemodialysis catheters, diagnostic pitfalls, and the challenge of catheter salvage.Frontiers in cellular and infection microbiology · 2026Review
- Determination of Bioactive Compounds, Antioxidant Capacity, Safety Assessment, and Antimicrobial Effect ofMolecules (Basel, Switzerland) · 2025Article
- Molecular landscape of the fungal plasma membrane and implications for antifungal action.Nature communications · 2025Article
- Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Article
- Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- ATR-FTIR spectroscopic markers indicating drug resistance in selected Candida strains.Scientific reports · 2025Article
- Signaling pathways governing the pathobiological features and antifungal drug resistance ofmBio · 2025Review
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Fungal infections due to Candida and Aspergillus species cause extensive morbidity and mortality, especially among immunosuppressed patients, and antifungal therapy is critical to patient management. Yet only a few drug classes are available to treat invasive fungal diseases, and this problem is compounded by the emergence of antifungal resistance. Echinocandin drugs are the preferred choice to treat candidiasis. They are the first cell wall-active agents and target the fungal-specific enzyme glucan synthase, which catalyzes the biosynthesis of β-1,3-glucan, a key cell wall polymer. Therapeutic failures occur rarely among common Candida species, with the exception of Candida glabrata, which is frequently multidrug resistant. Echinocandin resistance in susceptible species is always acquired during therapy. The mechanism of resistance involves amino acid changes in hot-spot regions of Fks subunits of glucan synthase, which decrease the sensitivity of the enzyme to drug. Cellular stress response pathways lead to drug adaptation, which promotes the formation of resistant fks strains. Clinical factors promoting echinocandin resistance include empiric therapy, prophylaxis, gastrointestinal reservoirs, and intra-abdominal infections. A better understanding of the echinocandin-resistance mechanism, along with cellular and clinical factors promoting resistance, will facilitate more effective strategies to overcome and prevent echinocandin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.